7:30 am
Networking Coffee & Registration

Refocusing IPF Drug Development
Where May Research & Trials Take Us in the Next 12 Months?

8:30 am Illuminating the last 12 months of IPF Drug Development Research

  • Fernando Martinez Chief of the Pulmonary and Critical Care Medicine Division, Weill Cornell Medical College

Synopsis

  • Highlighting the advancements of research in the last 12 months
  • Enlightening the critical inflection point of the IPF research in the next few years

9:00 am Living With IPF: A Patient Perspective

9:20 am Thinking to the Future: Where Will the IPF Drug Development Road Take Us?

Synopsis

Session Overview To Be Confirmed.

9:50 am
Speed Networking

Synopsis

  • This session is the perfect opportunity to get face-to-face time with the key opinion leaders in the IPF field
  • Establish meaningful business relationships to build upon for the rest of the conference and gain individual insight into the pioneering work ongoing

10:35 am
Morning Break & Networking

Basic Science & Early Translational Track

Late Translational & Clinical Track

Validating Novel In Vitro & In Vivo Models: Advancements, Predicting Efficacy, & Navigating Translatability

Utilizing Diagnostic, Prognostic, & Pharmacodynamic Biomarkers in Clinical Trials For a Precision Medicine Approach

11.00 Patient-Specific iPSCs as a Human Preclinical Model of Pulmonary Fibrosis - The epithelial-only patient-specific iAEC2 model system

  • Recapitulating key observations made previously in heterologous cell lines, mouse genetic models, and in vivo in the donors from whom the iPSCs were derived
  • Providing new insights into the potential role of AEC2s in the inception of pulmonary fibrosis
  • Discovering how patient-specific iPSCs are serving as a preclinical platform to test IPF therapeutics

Konstantinos Alysandratos, Assistant Professor, Boston University

11.00 Discussing the Latest in the PROLIFIC Consortium Biomarker Research to be Utilized in PF Clinical Trials

  • Moving beyond research using only assays to qualified assays for regulatory purposes and patient management
  • Effectively evaluating the 12 biomarkers in IPF research, biomarkers that reflect pharmacodynamics, mechanisms of action and prediction of response
  • Discussing the future direction of the PROLIFIC Consortium biomarker research

Peter Schafer, Scientific Vice President, Bristol Myers Squibb

11.30 IN MATRICO® IPF Model: 3D Human Lung Fibrosis Model to Improve Predictiveness and Accelerate Anti-Fibrotic Drug Development

  • Establishing a standardized 3D diseased modeling platform which incorporates minimally-processed, human lung extracellular matrix (ECM) to recapitulate the fibrotic disease environment.
  • Improving decision-making in early-stage anti-fibrotic drug development by comparing cell viability, protein secretion, and gene expression analysis with standard-of-care compounds and by correlating results with patient-specific data.

 

Evelyn Aranda, Director of Applications, Xylyx Bio, Inc.

11.30 Can Neoepitope Markers in the Extracellular Matrix Identify Therapeutic Effects on Epithelial Damage in IPF?

  • Reviewing how pulmonary Fibrosis (PF) is characterized by epithelial damage and changes to the extracellular matrix (ECM) composition
  • Assessing the ECM turnover using the neoepitope technology provides information about tissue equilibrium
  • Understanding how neoepitope biomarkers are prognostic in assessing ECM remodelling in fibrotic conditions such as PF

Diana Julia Leeming, Director of Fibrosis, Hepatic and Pulmonary Research, Nordic Bioscience

12.00 Harnessing a Variety of Preclinical Models to Support the Translatability of an Angiotensin Type 2 Receptor Agonist to Clinical Stage

  • Leveraging precision-cut human IPF lung slices, primary human lung cell co-cultures, receptor autoradiography, and different animals models of pulmonary fibrosis for preclinical IPF research
  • Divulging interim results from an ongoing phase 2 IPF clinical trial to showcase the potential of the therapeutic

Johan Raud, Chief Scientific Officer, Vicore Pharma AB

12.00 Biomarker Prime Time: Rethinking Clinical Research in IPF

  • Exploring if biomarkers are able to identify subpopulations of patients, predict disease progression and demonstrate impact of treatment
  • Are subpopulations of patients responding differently to treatment?
  • How to use the biomarker knowledge effectively in future clinical trials?

Yasmina Bauer, Director & Clinical Biomarker Leader, Galapagos

12:30 pm
Lunch & Networking

1.30 Leveraging Precision-Cut Lung Slices for IPF Research

  • Using precision-cut lung slices in translation, and reviewing the available data
  • Focusing upon the epithelial injury and how this looks different
  • Harnessing knowledge from other models to predict efficacy and navigate the risk of not translating

Hana Cernecka, Head of Inflammation, Bayer AG

1.30 Illuminating Pharmacodynamic Biomarkers: Using Biomarkers Efficiently in IPF Clinical Trials

  • Session Details to be Announced

Representative to be Confirmed, Pliant Therapeutics

2.00 Advancing Models that Reflect the Pharmacokinetic & Pharmacodynamic
Properties of Fibrosis

  • Highlighting the available data that suggests this approach will be most beneficial
  • Understanding the components of the model that reflect the pharmacokinetic and pharmacodynamic properties of fibrosis
  • Reflecting on the translatability and usability of this model

Meghan Clements, Principal Scientist, AbbVie

2.00 Panel Discussion: Discussing Effectively Utilizing Biomarkers in Clinical Trials: Which Biomarkers Give Earlier Indication at Trial?

Eric White, Senior Clinical Program Lead – ILD, Boehringer Ingelheim
Peter Schafer,
Scientific Vice President, Bristol Myers Squibb
Yasmina Bauer,
Director & Clinical Biomarker Leader, Galapagos

2.30 Discussing Collagen Type I mRNA Translation Inhibition in Idiopathic Pulmonary Fibrosis

  • Evaluating efficacy of compounds in-vivo in a bleomycin-induced IPF murine model and by Col-I quantification in an ex-vivo system using Human precision-cut-lung-slices (PCLS)
  • Highlighting compounds demonstrate tissue selectivity against Lung cells and show no effect on other tissues

Moty Klepfish, Principal Scientist, Fibrosis, Anima Biotech

2.30 Roundtable Interactive Discussion – Putting Biomarkers Into Action: Honing the Use of Biomarkers in the Clinic

An opportunity to break off into smaller groups and choose a discussion topic

  • Utilizing the available biomarkers effectively in clinical trials
  • Evaluating novel technologies that might give earlier indications at trial
  • Is the field closer to having an effective biomarker?

3.00 Panel Discussion: Novel In Vitro Models & Novel In Vivo Models Versus Bleomycin: Do They Better Represent IPF?`

Konstantinos Alysandratos, Assistant Professor, Boston University
Johan Raud,
Chief Scientific Officer, Vicore Pharma AB
Hana Cernecka,
Head of Inflammation, Bayer AG
Meghan Clements,
Principal Scientist, AbbVie

3:30 pm
Afternoon Break & Poster Session

Synopsis

Connect with your peers in a relaxed atmosphere and continue to forge new and existing relationships, whilst exploring the latest IPF drug development advances
To submit a poster or to find out more, contact info@hansonwade.com

Picture This: Novel Lung Imaging Techniques for IPF

4:30 pm Using the Revolutionary Technology Optical Coherence Tomography for IPF Assessment & Diagnosis

  • Lida Hariri Associate Professor, Massachusetts General Hospital, Harvard Medical School

Synopsis

  • Uncover how optical coherence tomography allows for pulmonologists to examine histological structures in patients’ lungs without the need for biopsy
  • Discussing the use of OCT for early diagnosis in ILD patients with low-confidence, clinical-radiologic diagnosis
  • Using repeat OCT imaging to detect microscopic disease changes over time, which may have potential for use in phase 2b and phase 3 clinical pharmaceutical trials

Renewing Genetic Approaches to Evolve Understanding of Genetic Pre-Disposure to IPF

5:00 pm Early Disease: Is it There if you Don’t See it?

Synopsis

  • Discussing ongoing efforts to study the biology of early and late disease
  • Highlighting earlier diagnosis and identification of at-risk individuals

5:15 pm Highlighting Haplotypes of Polymorphisms that Regulate Lymphocyte Functions Influence Risks for IPF

Synopsis

  • Discovering that permutations of particular immunomodulatory alleles modulate key cytotoxic lymphocyte functions and are highly associated with IPF
  • Using risk stratification and better understanding of these pathologic mechanisms could illuminate novel approaches for innovative, targeted therapies

5:45 pm Chair’s Closing Remarks

5:50 pm Drinks Reception in Partnership with the Three Lakes Foundation